Keeping up with Day 1 ESMO24 with Yüksel Ürün

The ESMO Congress 2024 (ESMO24) is taking place from 13-17 September 2024, in Barcelona.

ESMO24 is one of the most globally influential platforms in oncology, bringing together clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from across the world.

It is held through a Virtual Congress Platform, ESMO24 will serve as a critical hub for the dissemination of the latest cutting-edge cancer research, offering high-quality education and dynamic networking opportunities.

Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine in Turkey, shared a few insights from ESMO24:

ENGOT-cx11/GOG-3047/KEYNOTE-A18 Phase 3 Trial

Pembrolizumab and Chemoradiotherapy in advanced cervical cancer shows improved OS (HR 0.67) and PFS (HR 0.68) vs. placebo. A promising step forward in treatment!

Discussion by Karim Fizazi on PEACE-3

Insightful discussion by Karim Fizazi on PEACE-3 at ESMO24! This study suggests a potential change in practice, with Enzalutamide and Radium-223 emerging as a new SOC in mCRPC. Awaiting updates in ESMO guidelines!

Congratulations to Silke Gillessen and the team on the PEACE-3 study results

PEACE-3 trial shows a significant improvement in rPFS and OS with Enzalutamide and Ra223 in mCRPC with bone metastases. Time to SSE remained similar at 24 months (18%).

Reuniting with wonderful friends

Grateful for these moments of connection and shared passion. Here’s to many more inspiring conversations!

Sexual health in cancer patients

Congratulations Cristiane D Bergerot.

Addressing sexual health in cancer patients is crucial for comprehensive care.

Excellent session on GU tumors (non-prostate)

What a crew!

Just after an excellent session on GU tumors (non-prostate) at ESMO24. Amazing insights from the experts.

ESMO is even better when catching up with friends!

ESMO 2024 kicks off

ESMO 2024 kicks off! Let’s unite in advancing oncology, bringing together cutting-edge research and innovation to improve patient care.

For more updates on ESMO24, visit oncodaily.com.